HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Meningococcal Infections

Infections with bacteria of the species NEISSERIA MENINGITIDIS.
Also Known As:
Infections, Meningococcal; Meningococcal Disease; Infection, Meningococcal; Meningococcal Diseases; Meningococcal Infection; Septicemia, Meningococcal; Meningococcal Septicemia
Networked: 2111 relevant articles (187 outcomes, 180 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Meningitis
2. Meningococcal Infections
3. Human Influenza (Influenza)
4. Typhoid Fever (Typhoid)
5. Communicable Diseases (Infectious Diseases)

Experts

1. Borrow, Ray: 47 articles (12/2022 - 07/2002)
2. Taha, Muhamed-Kheir: 30 articles (12/2022 - 10/2003)
3. Pollard, Andrew J: 27 articles (12/2022 - 02/2003)
4. Maiden, Martin C J: 26 articles (01/2022 - 02/2003)
5. Harrison, Lee H: 21 articles (01/2018 - 01/2006)
6. Granoff, Dan M: 19 articles (12/2021 - 04/2002)
7. Wang, Xin: 19 articles (12/2021 - 02/2009)
8. MacNeil, Jessica R: 19 articles (01/2020 - 01/2010)
9. Pizza, Mariagrazia: 18 articles (12/2021 - 06/2002)
10. Balmer, Paul: 15 articles (01/2022 - 06/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Meningococcal Infections:
1. VaccinesIBA
01/01/2014 - "As vaccines against the most frequent bacterial isolates in this study are available and licensed, these results highlight the need for broad based protection against meningococcal disease in Turkey."
05/19/2017 - "In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease* (Category A) (3), and in June 2015, ACIP recommended that adolescents and young adults aged 16-23 years may be vaccinated with MenB vaccines to provide short-term protection against most strains of serogroup B meningococcal disease (Category B†) (4). "
01/01/2016 - "On the basis of epidemiologic and antibody persistence data, the American Academy of Pediatrics agrees with the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that either vaccine may be administered to healthy adolescents and young adults 16 through 23 years of age (preferred ages are 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease (category B recommendation)."
10/23/2015 - "At its June 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended that adolescents and young adults aged 16–23 years may be vaccinated with a serogroup B meningococcal (MenB) vaccine to provide short-term protection against most strains of serogroup B meningococcal disease. "
08/01/2004 - "The MCC vaccine program has been highly effective in Scotland, leading to substantial reductions in serogroup C meningococcal disease and meningococcal mortality, with no adverse effects on other groups."
2. AntibodiesIBA
3. Conjugate VaccinesIBA
4. Meningococcal Vaccines (Meningococcal Vaccine)IBA
5. AntigensIBA
6. Complement System Proteins (Complement)IBA
7. Polysaccharides (Glycans)IBA
8. Proteins (Proteins, Gene)FDA Link
9. Immunoglobulin G (IgG)IBA
10. Anti-Bacterial Agents (Antibiotics)IBA

Therapies and Procedures

1. Therapeutics
2. Chemoprevention
3. Critical Care (Surgical Intensive Care)
4. Surgical Amputation (Amputations)
5. Injections